References
- Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol 2015; 67: 470-479; PMID:25306226; http://dx.doi.org/10.1016/j.eururo.2014.09.049
- De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KM, Jones RJ, Goodman Jr OB, Saad F, et al. Abiraterone and increased survival in metastatic prostate cancer. New Eng J Med 2011; 364: 1995-2005; PMID:21612468; http://dx.doi.org/10.1056/NEJMoa1014618
- Barrie SE, Jarman M, Potter GA. 17-substituted steroids useful in cancer treatment. Patent WO 1993020097 A1. 14 Oct 1993.
- Potter GA, Barrie SE, Jarman M, Rowlands MG. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxlase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem 1995; 23: 2463-2471; PMID:7608911; http://dx.doi.org/10.1021/jm00013a022
- Li Z, Bishop AC, Alyamani M, Garcia GA, Dreicer R, Bunch D, Liu J, Upadhyay SK, Auchus RJ, Sharifi N. Conversion of abiraterone to D4A drives anti-tumor activity in prostate cancer. Nature 2015; 523: 347-351; PMID:26030522; http://dx.doi.org/10.1038/nature14406
- Barrie SE, Potter GA, Goddard PM, HAyned BP, Dowsett M, Jarman M. Pharmacology of novel sterioidal inhibitors of cytochrome P45017α (17α-hydroxylase/C17–20 lyase). J Sterois Biochem Mol Biol 1994; 50: 267-273; PMID:7918112; http://dx.doi.org/10.1016/0960-0760(94)90131-7
- Wu G, Huang S, Nastiuk KL, Li J, Gu J, Wu M, Zhang Q, Lin H, Wu D. Varient allele of HSD3B1 increases progression to castrate resistant prostate cancer. Prostate 2015; 75: 777-782; PMID:25731771; http://dx.doi.org/10.1002/pros.22967